Trial Profile
A Phase 1-2 Multicenter, Open Label Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Dec 2023
Price :
$35
*
At a glance
- Drugs H3B-6545 (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions
- Sponsors Eisai Inc; H3 Biomedicine
- 22 Dec 2023 Status changed from active, no longer recruiting to completed.
- 01 Feb 2023 Planned End Date changed from 31 Dec 2022 to 1 Oct 2023.
- 01 Feb 2023 Planned primary completion date changed from 31 Dec 2022 to 1 Oct 2023.